IP Library › Granted Patent US 50,631
Granted Patent E1
US 50,631 · App. 17/365,293 · Granted Oct 14, 2025

ROR1 antibody immunoconjugates

Inventors: Brian Lannutti (Solana Beach, CA); Katti Jessen (San Diego, CA); Thanh-Trang Vo (San Diego, CA); Jeffry Dean Watkins (Encinitas, CA)
A61K47/6849A61K38/05A61K39/3955A61K45/06A61K47/6803A61K47/6811A61K47/6871A61P35/00C07K16/2803A61K2039/505A61K2039/572C07K2317/24C07K2317/56C07K2317/565C07K2317/732C07K2317/734C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 50,631
App. No.
17/365,293
Granted
Oct 14, 2025
Kind
E1
Abstract

Provided herein are immunoconjugates comprising an anti-ROR-1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR-1 expressing cancers.

Claims (160)

1. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is

ADC-A, having the structure

wherein Ab in the structure is the antibody of the formula:

Ab-[(L) m -(D)] n

wherein Ab is an antibody that binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1), and wherein

Ab comprises:

(a) a heavy chain variable region (V H ) comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 7, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 8; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 9, and

(b) a light chain variable region (V L ) comprising an LCDRI comprising the amino acid sequence of SEQ ID NO: 10; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 11; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 12,

each occurrence of the group -[(L) m -(D)] has the structure:

wherein represents the site of attachment to a sulfur atom on a cysteine residue on [the antibody] Ab; and

n is an integer from 1 to 8.

2. The immunoconjugate of claim 1 , wherein the heavy chain and light chain of the antibody Ab comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

3. The immunoconjugate of claim 2 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7 n is an integer from 1 to 5.

4. A pharmaceutical composition comprising the immunoconjugate of claim 1 and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 4 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine rapamycin (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

6. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 1 .

7. A method of making the immunoconjugate of claim 1 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating monomethyl auristatin E (MMAE) to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

8. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-E, having the structure

wherein Ab in the structure is the antibody.

9. The immunoconjugate of claim 8 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

10. The immunoconjugate of claim 8 , wherein the ratio of the cytoxic drug moiety to the antibody is 1 to 7.

11. A pharmaceutical composition comprising the immunoconjugate of claim 8 and a pharmaceutically acceptable excipient.

12. The pharmaceutical composition of claim 11 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

13. A method of treating a ROR 1 -expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 8 .

14. A method of making the immunoconjugate of claim 8 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating monomethyl auristatin E (MMAE) to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:5.

15. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-H, having the structure,

wherein Ab in the structure is the antibody.

16. The immunoconjugate of claim 15 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

17. The immunoconjugate of claim 16 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

18. A pharmaceutical composition comprising the immunoconjugate of claim 15 and a pharmaceutically acceptable excipient.

19. The pharmaceutical composition of claim 18 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton'tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2(Bcl-2) inhibitor, mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

20. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 15 .

21. A method of making the immunoconjugate of claim 15 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating azonafide to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 6.

22. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-J, having the structure

wherein Ab in the structure is the antibody.

23. The immunoconjugate of claim 22 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

24. The immunoconjugate of claim 23 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

25. A pharmaceutical composition comprising the immunoconjugate of claim 22 and a pharmaceutically acceptable excipient.

26. The pharmaceutical composition of claim 25 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (MTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

27. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 22 .

28. A method of making the immunoconjugate of claim 22 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating Duocarmycin TM to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

29. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-K, having the structure

wherein Ab in the structure is the antibody.

30. The immunoconjugate of claim 29 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

31. The immunoconjugate of claim 30 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

32. A pharmaceutical composition comprising the immunoconjugate of claim 29 and a pharmaceutically acceptable excipient.

33. The pharmaceutical composition of claim 32 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

34. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 29 .

35. A method of making the immunoconjugate of claim 29 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating pyrrolobenzodiazepine (PBD) to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

36. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-L, having the structure

wherein Ab in the structure is the antibody.

37. The immunoconjugate of claim 36 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

38. The immunoconjugate of claim 37 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

39. A pharmaceutical composition comprising the immunoconjugate of claim 36 and a pharmaceutically acceptable excipient.

40. The pharmaceutical composition of claim 39 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

41. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 36 .

42. A method of making the immunoconjugate of claim 36 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and conjugating monomethyl auristatin E (MMAE) to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

43. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-M, having the structure

wherein Ab in the structure is the antibody.

44. The immunoconjugate of claim 43 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

45. The immunoconjugate of claim 44 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

46. A pharmaceutical composition comprising the immunoconjugate of claim 43 and a pharmaceutically acceptable excipient.

47. The pharmaceutical composition of claim 46 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

48. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 43 .

49. A method of making the immunoconjugate of claim 43 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating monomethyl auristatin E (MMAE) to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

50. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-N, having the structure

wherein Ab in the structure is the antibody.

51. The immunoconjugate of claim 50 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

52. The immunoconjugate of claim 51 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

53. A pharmaceutical composition comprising the immunoconjugate of claim 50 and a pharmaceutically acceptable excipient.

54. The pharmaceutical composition of claim 53 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

55. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 50 .

56. A method of making the immunoconjugate of claim 50 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and conjugating PNU-159682 to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

57. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-O, having the structure

wherein Ab in the structure is the antibody.

58. The immunoconjugate of claim 57 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

59. The immunoconjugate of claim 58 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

60. A pharmaceutical composition comprising the immunoconjugate of claim 57 and a pharmaceutically acceptable excipient.

61. The pharmaceutical composition of claim 60 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

62. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 57 .

63. A method of making the immunoconjugate of claim 57 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating PNU-159682 to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

64. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-P, having the structure

wherein Ab in the structure is the antibody.

65. The immunoconjugate of claim 64 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

66. The immunoconjugate of claim 65 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

67. A pharmaceutical composition comprising the immunoconjugate of claim 64 and a pharmaceutically acceptable excipient.

68. The pharmaceutical composition of claim 67 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

69. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 64 .

70. A method of making the immunoconjugate of claim 64 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and conjugating PNU-159682 to the antibody; wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

71. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-Q, having the structure

wherein Ab in the structure is the antibody.

72. The immunoconjugate of claim 71 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

73. The immunoconjugate of claim 72 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

74. A pharmaceutical composition comprising the immunoconjugate of claim 71 and a pharmaceutically acceptable excipient.

75. The pharmaceutical composition of claim 74 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

76. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 71 .

77. A method of making the immunoconjugate of claim 71 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating monomethyl auristatin E (MMAE) to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

78. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the V H and V L of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate is ADC-R, having the structure

wherein Ab in the structure is the antibody.

79. The immunoconjugate of claim 78 , wherein the heavy chain and light chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 3 and 4, respectively.

80. The immunoconjugate of claim 79 , wherein the ratio of the cytotoxic drug moiety to the antibody is 1 to 7.

81. A pharmaceutical composition comprising the immunoconjugate of claim 78 and a pharmaceutically acceptable excipient.

82. The pharmaceutical composition of claim 81 , further comprising an additional therapeutic agent selected from the group consisting of a Bruton's tyrosine kinase (BTK) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, a mammalian target of rapamycine (mTOR) inhibitor, and a phosphoinositide 3-kinase (PI3K) inhibitor.

83. A method of treating a ROR1-expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 78 .

84. A method of making the immunoconjugate of claim 78 , comprising:

providing an antibody that specifically binds to human receptor tyrosine kinase like orphan receptor 1 (ROR1); and

conjugating PNU-159682 to the antibody;

wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:5 and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:6.

85. The immunoconjugate of claim 3 , wherein n is 4.

86. The immunoconjugate of claim 1 , wherein Ab comprises: a heavy chain comprising an amino acid sequence at least 95% identical to that of SEQ ID NO: 3, and a light chain comprising an amino acid sequence at least 95% identical to that of SEQ ID NO: 4.

87. A method of treating a human receptor tyrosine kinase like orphan receptor 1 (ROR1) expressing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the immunoconjugate of claim 1.

88. A method of making the immunoconjugate of claim 1 , comprising the steps:

(i) reducing the cysteine residues of Ab of claim 1 by contacting Ab with a reducing agent; and

(ii) conjugating one or more thiol groups of the reduced cysteine moieties of the product of step (i) with the maleimide group of the following linker/payload moiety: 6-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-VC-PAB-MMAE).

89. The method of claim 87 , wherein the human receptor tyrosine kinase like orphan receptor 1 (ROR1) expressing cancer is a lymphoma.

90. The method of claim 89 , wherein the lymphoma is selected from diffuse large β-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).

91. The method of claim 87 , further comprising administering to the patient one or more additional therapeutic agents, wherein the one or more additional therapeutic agents are selected from rituximab, cyclophosphamide, vincristine, prednisone, gemcitabine, daunorubicin hydrochloride, and a Bruton's tyrosine kinase (BTK) inhibitor.

92. The immunoconjugate of claim 86 , wherein Ab comprises: a V H comprising the amino acid sequence of SEQ ID NO: 5, and a V L comprising the amino acid sequence of SEQ ID NO: 6.

93. A method of making the immunoconjugate of claim 3 , comprising the steps:

(i) reducing the cysteine residues of Ab of claim 3 by contacting Ab with a reducing agent; and

(ii) conjugating one or more thiol groups of the reduced cysteine moieties of the product of step (i) with the maleimide group of the following linker/payload moiety: 6-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-VC-PAB-MMAE).

94. A method of making the immunoconjugate of claim 86 , comprising the steps:

(i) reducing the cysteine residues of Ab of claim 86 by contacting Ab with a reducing agent; and

(ii) conjugating one or more thiol groups of the reduced cysteine moieties of the product of step (i) with the maleimide group of the following linker/payload moiety: 6-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-VC-PAB-MMAE).

95. A method of making the immunoconjugate of claim 92 , comprising the steps:

(i) reducing the cysteine residues of Ab of claim 92 by contacting Ab with a reducing agent; and

(ii) conjugating one or more thiol groups of the reduced cysteine moieties of the product of step (i) with the maleimide group of the following linker/payload moiety: 6-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-VC-PAB-MMAE).

96. The immunoconjugate of claim 86 , wherein n is 4.

97. The immunoconjugate of claim 92 , wherein n is 4.

98. The method of claim 90 , wherein the lymphoma is diffuse large β-cell lymphoma (DLBCL).

99. The method of claim 98 , further comprising administering to the patient one or more additional therapeutic agents, wherein the one or more additional therapeutic agents are selected from rituximab, cyclophosphamide, vincristine, prednisone, daunorubicin hydrochloride, and gemcitabine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2021
From: LANNUTTI, BRIAN; JESSEN, KATTI; VO, THANH-TRANG; WATKINS, JEFFRY DEAN
To: VELOSBIO INC.
Reel/Frame 057943/0327 →
Continuity (5)
Continuation 16016238 · Jun 22, 2018
Provisional Application 62524386 · Jun 23, 2017
Provisional Application 62524388 · Jun 23, 2017
Provisional Application 62524382 · Jun 23, 2017
Reissue 16027967 · Jul 5, 2018
References Cited (155)
US 6821783B1 · Comely et al. · 2004 [cited by applicant]
US 6884869B2 · Senter et al. · 2005 [cited by applicant]
US 7498298B2 · Doronina et al. · 2009 [cited by applicant]
US 7659241B2 · Senter et al. · 2010 [cited by applicant]
US 7829531B2 · Senter et al. · 2010 [cited by applicant]
US 7851437B2 · Senter et al. · 2010 [cited by applicant]
US 8212009B2 · Kipps et al. · 2012 [cited by applicant]
US 8288352B2 · Doronina et al. · 2012 [cited by applicant]
US 8609105B2 · Senter et al. · 2013 [cited by applicant]
US 8697688B2 · Howard et al. · 2014 [cited by applicant]
US 8742076B2 · Cohen et al. · 2014 [cited by applicant]
US 8900589B2 · Beria et al. · 2014 [cited by applicant]
US 8936910B2 · Mitsch et al. · 2015 [cited by applicant]
US 9150647B2 · Mellstedt et al. · 2015 [cited by applicant]
US 9089614B2 · Lin et al. · 2015 [cited by applicant]
US 9217040B2 · Kipps et al. · 2015 [cited by applicant]
US 9228023B2 · Rohlff et al. · 2016 [cited by applicant]
US 9242014B2 · Kipps et al. · 2016 [cited by applicant]
US 9266952B2 · Teige · 2016 [cited by applicant]
US 9316646B2 · Rader et al. · 2016 [cited by applicant]
US 9523695B2 · Kipps et al. · 2016 [cited by applicant]
US 9758591B2 · Kipps et al. · 2017 [cited by applicant]
US 9933434B2 · Kipps et al. · 2018 [cited by applicant]
US 9938350B2 · Kipps et al. · 2018 [cited by applicant]
US 10316080B2 · Smith et al. · 2019 [cited by applicant]
US 20080050310A1 · Ebens, Jr. · 2008 [cited by examiner]
US 20090258442A1 · Polakiewicz et al. · 2009 [cited by applicant]
US 20090311249A1 · Gianni et al. · 2009 [cited by applicant]
US 20110178070A1 · Gong · 2011 [cited by examiner]
US 20120058051A1 · Rader et al. · 2012 [cited by applicant]
US 20120282177A1 · Rohlff et al. · 2012 [cited by applicant]
US 20130028919A1 · Howard et al. · 2013 [cited by applicant]
US 20130101607A1 · Kipps et al. · 2013 [cited by applicant]
US 20130131139A1 · Tyner et al. · 2013 [cited by applicant]
US 20130251642A1 · Rader et al. · 2013 [cited by applicant]
US 20130309256A1 · Lyon et al. · 2013 [cited by applicant]
US 20140127239A1 · Howard · 2014 [cited by applicant]
US 20140286970A1 · Jeffrey et al. · 2014 [cited by applicant]
US 20140294851A1 · Nguyen · 2014 [cited by applicant]
US 20150037360A1 · Smith · 2015 [cited by applicant]
US 20150232569A1 · Kipps · 2015 [cited by examiner]
US 20160022833A1 · Bregeon · 2016 [cited by applicant]
US 20160193355A1 · Qin et al. · 2016 [cited by applicant]
US 20160208018A1 · Chen et al. · 2016 [cited by applicant]
US 20170014311A1 · Ishizuka et al. · 2017 [cited by applicant]
US 20170319709A1 · Tikhomirov · 2017 [cited by applicant]
US 20170368173A1 · Kipps et al. · 2017 [cited by applicant]
US 20220133901A1 · Lannutti · 2022 [cited by examiner]
US 20220152214A1 · Miller · 2022 [cited by examiner]
CN 103429618A · 2013 [cited by applicant]
CN 105473616A · 2016 [cited by applicant]
CN 105813655A · 2016 [cited by applicant]
EP 154613B9 · 2012 [cited by applicant]
EP 1545613B9 · 2012 [cited by applicant]
EP 2353611B1 · 2015 [cited by applicant]
JP 2019509021A · 2019 [cited by applicant]
JP 7245239B2 · 2023 [cited by applicant]
WO WO2010124188A1 · 2010 [cited by applicant]
WO WO2011159847A2 · 2011 [cited by applicant]
WO WO2012045085A1 · 2012 [cited by applicant]
WO 2014031174A1 · 2014 [cited by applicant]
WO WO2014031171A1 · 2014 [cited by applicant]
WO WO2014080251A1 · 2014 [cited by applicant]
WO WO2014145090A1 · 2014 [cited by applicant]
WO WO2014167022A1 · 2014 [cited by applicant]
WO WO2014177042A1 · 2014 [cited by applicant]
WO WO2014197854A1 · 2014 [cited by applicant]
WO WO2015038426A1 · 2015 [cited by applicant]
WO WO2015057699A2 · 2015 [cited by applicant]
WO 2015198332A1 · 2015 [cited by applicant]
WO WO2015198332 · 2015 [cited by applicant]
WO WO2016055592A1 · 2016 [cited by applicant]
WO WO2016055593A1 · 2016 [cited by applicant]
WO 2016094873A2 · 2016 [cited by applicant]
WO WO2016094873 · 2016 [cited by applicant]
WO WO2016115559A1 · 2016 [cited by applicant]
WO 2016187220A2 · 2016 [cited by applicant]
WO WO2016187220 · 2016 [cited by applicant]
WO WO2017072361A1 · 2017 [cited by applicant]
WO 2017127664A1 · 2017 [cited by applicant]
WO WO2017127499A1 · 2017 [cited by applicant]
WO WO2017127664 · 2017 [cited by applicant]
WO WO2018119314A1 · 2018 [cited by applicant]
WO 2018237335A1 · 2018 [cited by applicant]
WO 2020160527A1 · 2020 [cited by applicant]
Li et al. Cancef Biology & Therapy. vol. 17, No. 4, 346-354. (Year: 2016). [cited by examiner]
Karvonen. Biochemical Society Transactions (Apr. 2017) 45 457-464 (Year: 2017). [cited by examiner]
Agarwal, Paresh et al., A Pictet-Spengler ligation for protein chemical modification, Proc Natl Acad Sci USA, 2013, 46-51, 110(1). [cited by applicant]
Axup et al., Synthesis of site-specific antibody-drug conjugates using unnatural amino acids, Proc. Natl. Acad. Sci. USA, 2012, Issue 40, pp. 16101-16106, 109. [cited by applicant]
Balakrishnan, Ashwini et al., Analysis of ROR1 protein expression in human cancer and normal tissues, Clinical Cancer Research, 2017, 3061-3071, 23(12). [cited by applicant]
Berger, Carolina et al., Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells, Cancer Immunology Research, 2015, 206-216, 3. [cited by applicant]
Bicocca, Vincent T. et al., Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia, Cancer Cell, 2012, 656-667, 22(5). [cited by applicant]
Blaney, Paul et al., Traceless solid-phase organic synthesis, Chem Rev, 2002, 2607-2624, 102(7). [cited by applicant]
Bulmus, Volga et al., A new pH-responsive and glutathione-reactive, endosomal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs, Journal of Controlled Release, 2003, 105-120, 93(2). [cited by applicant]
Casi, Giulio et al., Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery, J Am Chem Soc, 2012, 5887-5892, 134(13). [cited by applicant]
Castaneda, Lourdes et al., Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation, Chem Commun (Camb), 2013, 8187-8189, 49(74). [cited by applicant]
Cheson, Bruce D. et al., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, Journal of Clinical Oncology, 2014, 3059-3068, 32(27). [cited by applicant]
Choi, Michael et al., Durable and specific inhibition of ROR1 signaling associates with prolonged progression free survival in patients with chronic lymphocytic leukemia treated with cirmluzumab, Blood, 2017, 3 pages, 1… [cited by applicant]
Choi, Michael Y. et al., Pre-clinical specificity and safety of UC 961, a first-in-class monoclonal antibody targeting ROR1, Clinical Lymphoma, Myeloma & Leukemia, 2015, S167-S169, 15. [cited by applicant]
Cui, Bing et al., Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors, Blood, 2013, 1637, 122(21). [cited by applicant]
Cui, Bing et al., High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia, Blood, 2016, 2931-2940, 128(25). [cited by applicant]
Cui, Bing et al., Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis, Cancer Research, 2013, 3649-3660, 73(12). [cited by applicant]
Daneshmanesh, A.H. et al., Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells, Leukemia, 2012, 1348-1355, 26(6). [cited by applicant]
Daneshmanesh, Amir Hossein et al., Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies, Leukemia & Lymphoma, 2013, 843-850, 54(4). [cited by applicant]
Dawson, Philip E. et al., Modulation of reactivity in native chemical ligation through the use of thiol additives, Journal of the American Chemical Society, 1997, 4325-4329, 119(19). [cited by applicant]
Dawson, Philip E. et al., Synthesis of proteins by native chemical ligation, Science, 1994, 776-779, 266. [cited by applicant]
Dennler, Patrick et al., Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates, Bioconjugate Chemistry, 2014, 569-578, 25(3). [cited by applicant]
El-Sayed, Mohamed E.H. et al., Rational design of composition and activity correlations for pH-responsive and glutathione-reactive polymer therapeutics, Journal of Controlled Release, 2005, 417-427, 104(2). [cited by applicant]
Flanary, Suzanne et al., Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation, Bioconjugate Chemistry, 2009, 241-248, 20(2). [cited by applicant]
Fukuda, Tetsuya et al., Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a, Proc. Natl. Acad. Sci. USA, 2008, 3047-3052, 105(8). [cited by applicant]
Gentile, Alessandra et al., Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis, Cancer Research, 2011, 3132-3141, 71(8). [cited by applicant]
Gong, Xing et al., LGR5-targeted antibody-drug conjugate eradicates gastrointestinal tumors and prevents recurrence, Molecular Cancer Therapeutics, 2016, 1580-1590, 15(7). [cited by applicant]
Grawunder, Ulf, Antibody drug conjugates with anthracycline payload induce tumor-selective antitumor immunity and exhibit a favorable safety profile in cynomolgus monkey toxicology studies, Proc Amer Assoc Cancer Res, 2… [cited by applicant]
Hackeng, Tilman M. et al., Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology, Proc Natl Acad Sci USA, 1999, 10068-10073, 96(18). [cited by applicant]
Hejesen, Christian et al., A traceless aryl-triazene linker for DNA-directed chemistry, Organic & Biomolecular Chemistry, 2013, 2493-2497, 11(15). [cited by applicant]
Henry, Scott M. et al., pH-responsive poly(styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery, Biomacromolecules, 2006, 2407-2414, 7(8). [cited by applicant]
Hojjat-Farsangi, Mohammad et al., Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells, PLoS One, 2013, 1-10, 8(4):e61167. [cited by applicant]
Hojjat-Farsangi, Mohammad et al., The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells, PLoS One, 2013, 1-9, 8(10):e78339. [cited by applicant]
Ida, Lisa et al., Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinom… [cited by applicant]
Janovska, Pavlina et al., Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia, Clinical Cancer Research, 2016, 459-469, 22(2). [cited by applicant]
Jones, Rachel A. et al., Poly(2-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles, Biochem. J., 2003, 65-75, 372 (Pt 1). [cited by applicant]
Kamath, Amrita V. et al., Preclinical pharmacokinetic considerations for the development of antibody drug conjugates, Pharm. Res., 2015, 3470-3479, 32. [cited by applicant]
Kolb, Ryan et al., ROR1 is an intriguing target for cancer therapy, Molecular Enzymology and Drug Targets, 2016, 1-3, 2 (1:4). [cited by applicant]
Kovtun, Yelena V. et al., Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen, Cancer Research, 2006, 3214-3221, 66(6). [cited by applicant]
Li, Fu et al., Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models, Cancer Research, 2016, 2710-2719, 76(9). [cited by applicant]
Li, Ping et al., Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells, PLoS One, 2010, 1-11, 5(7):e11859. [cited by applicant]
Loganzo, Frank et al., Mechanisms of resistance to antibody-drug conjugates, Molecular Cancer Therapeutics, 2016, 2825-2834, 15(12). [cited by applicant]
Lyon, Robert P. et al., Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates, Nature Biotechnology, 2014, 1059-1062, 32(10). [cited by applicant]
Mao, Zhengrong et al., IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) repres… [cited by applicant]
O'Connell, Michael P. et al., Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2, Cancer Discovery, 2013, 1378-1393, 3(12). [cited by applicant]
Okeley, Nicole M. et al., Correction: Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate, Clinical Cancer Research, 2011, 5524, 17(16). [cited by applicant]
Okeley, Nicole M. et al., Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate, Clinical Cancer Research, 2010, 888-897, 16(3). [cited by applicant]
Patterson, James T. et al., Improving the serum stability of site-specific antibody conjugates with sulfone linkers, Bioconjugate Chemistry, 2014, 1402-1407, 25. [cited by applicant]
Saber, Haleh et al., An FDA oncology analysis of antibody-drug conjugates, Regulatory Toxicology and Pharmacology, 2015, 444-452, 71(3). [cited by applicant]
Sochaj, Alicja M. et al., Current methods for the synthesis of homogeneous antibody-drug conjugate, Biotechnology Advances, 2015, 775-784, 33 (6 Pt 1). [cited by applicant]
Specht, Jennifer M. et al., A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR), Proc Amer… [cited by applicant]
Strop, Pavel et al., Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates, Chemistry & Biology, 2013, 161-167, 20(2). [cited by applicant]
Van Der Weyden, Ca et al., Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions, Blood Cancer Journal, 2017, 1-10, 7(9):e603. [cited by applicant]
Widhopf, George F. et al., ROR1 can interact with TCL 1 and enhance leukemogenesis in Eμ-TCL 1 transgenic mice, Proc Natl Acad Sci USA, 2014, 793-798, 111(2). [cited by applicant]
Wu, Bin et al., Building complex glycopeptides: Development of a cysteine-free native chemical ligation protocol, Angew Chem Int Ed Engl, 2006, 4116-4125, 45(25). [cited by applicant]
Wu, Peng et al., Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag, Proc Natl Acad Sci USA, 2009, 3000-3005, 106(9). [cited by applicant]
Yamaguchi, Tomoya et al., NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma, Cancer Cell, 2012, 348-361, 21(3). [cited by applicant]
Yang, Jiahui et al., Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies, PLoS One, 2011, 1-15, 6(6):e21018. [cited by applicant]
Yessine, Marie-Andree et al., Characterization of the membrane-destabilizing properties of different pH-sensitive methacrylic acid copolymers, Biochimica et Biophysica Acta, 2003, 28-38, 1613(1-2). [cited by applicant]
Yu, J. et al., Cirmtuzumab inhibits Wnt5a-induced Rac1-activation in chronic lymphocytic leukemia treated with ibrutinib, Leukemia, 2017, 1333-1339, 31(6). [cited by applicant]
Yu, Jian et al., Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma, Oncotarget, 2018, 24731-24736, 9(37). [cited by applicant]
Yu, Jian et al., Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation, The Journal of Clinical Investigation, 2016, 585-598, 126(2). [cited by applicant]
Zhang, Huilin et al., ROR1 expression correlated with poor clinical outcome in human ovarian cancer, Scientific Reports, 2014, 1-7, 4:5811. [cited by applicant]
Zhang, Suping et al., ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth, PLoS One, 2012, 1-12, 7(3):e31127. [cited by applicant]
Zhang, Suping et al., The onco-embryonic antigen ROR1 is expressed by a variety of human cancer, The American Journal of Pathology, 2018, 1903-19010, 181(6). [cited by applicant]
Dillon, Thomas M. et al., Structural and Functional Characterization of Disulfide Isoforms of the Human lgG2 Subclass, Journal of Biological Chemistry, 2008, 16206-16215, 283(23). [cited by applicant]
Keating, Gillian M., Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma, Targeted Oncology, vol. 10, p. 141-151, 2015. [cited by applicant]
Dillon et al. (Journal of Biological Chemistry, 283(23): 16206-16215, 2008, Supplementary Material. [cited by examiner]
Grawunder et al., “Development of best-in-class, homogeneous Antibody Drug Conjugates (ADCs) for highly effective and safer cancer therapy,” presented at World ADC Congress, Berlin, Feb. 8-9, (2016). [cited by applicant]
Grawunder et al., “Preclinical validation of site-specically conjugated ADCs with potent anthracycline payloads in solid and hematological tumor models,” presented at World ADC Congress, Berlin, Mar. 27, 2018. [cited by applicant]